EMA-EUnetHTA Parallel Consultation
Parallel consultation between EUnetHTA and the European Medicines Agency As of July 2017, EUnetHTA and the European Medicines Agency (EMA) offer parallel consultations on evidence generation plans. This aims to allow medicine developers to obtain feedback from regulators and health technology assessment (HTA) bodies on their development plans to support decision-making on marketing authorisation, health […]
EMA-EUnetHTA meeting June 2017 – Final minutes
20170608 – EMA-EUnetHTA Meeting Minutes – FINAL
EMA-EUnetHTA meeting Dec 2016 – Final minutes
EMA-EUnetHTA meeting Dec 2016 – Final minutes
EMA-EUnetHTA Joint Work Plan for 2017-2020
This is the EMA-EUnetHTA Joint Work Plan for 2017-2020 EMA-EUnetHTA work plan 2017 – 2020 – for publication
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report WP7 Activity 1 Report Template for deliverable 7.1 Annex 1_agency data Annex 2_case studies
Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Project plan_PTJA03_Alectinib_final
Updated EVIDENT database
The Evidence database on new technologies (EVIDENT Database) stores information on assessment, coverage and recommendations/requests for additional studies arising from HTA reports for promising technologies in Europe. Access is currently restricted to EUnetHTA Partners and Associates. The database was developed by HAS during Joint Action 1. Two upgraded database versions have been released during JA2 […]
Training Strategy
The objectives of EUnetHTA Joint Action 2, Work Package 2 (WP2) was to “increase awareness and understanding of the usefulness of the EUnetHTA tools, methods and results among EUnetHTA partners and stakeholders”. In order to fulfil this objective, WP2 has organized various training activities during JA2 (i.e. face-to-face training courses, e-learning and webinars). Based on […]
Training material on the HTA Core Model
HTA Core Model training materials New to the HTA Core Model? Uncertain about whether and how to use the Model or and the HTA Core Model Online? Now all training materials on the HTA Core Model have been compiled into a 2-page overview that helps you becoming acquainted with the Model and its use! Overview […]
Submission template for Pharmaceuticals and Submission template for Medical Devices
The EUnetHTA evidence submission template was developed from an analysis of evidence requirements for reimbursement in Europe. It is a tool that agencies can use to request evidence from companies to support their HTA and reimbursement processes. The tool covers relative effectiveness assessment including a description of the health condition and health technology, as well […]
